Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 10/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126308 | 0.84 | MAPT (0.50) | CYP1A2CYP17A1NR3C1ALDH1A1L3MBTL1 | |
| SCHEMBL27837486 | 0.84 | CYP1A2 (0.39) | CYP1A2CYP17A1CCR1ALDH1A1 | |
| SCHEMBL441916 | 0.83 | CCR1 (0.46) | CYP1A2CYP17A1CCR1NR3C1PGR | |
| SCHEMBL303982 | 0.82 | CYP17A1 (0.56) | CYP1A2CYP17A1CCR1NR3C1PGR | |
| SCHEMBL28772690 | 0.81 | CCR1 (0.38) | CYP1A2CYP17A1CCR1 | |
| SCHEMBL4113695 | 0.81 | CYP17A1 (0.54) | CYP1A2CYP17A1CCR1NR3C1PGR | |
| SCHEMBL443587 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP17A1CCR1NR3C1PGR | |
| SCHEMBL567717 | 0.81 | CYP17A1 (0.45) | CYP1A2CYP17A1CCR1NR3C1ALDH1A1 | |
| SCHEMBL25342945 | 0.79 | SCN9A (0.45) | CYP1A2CYP17A1 | |
| SCHEMBL4112054 | 0.79 | SCN9A (0.41) | CYP1A2CYP17A1CCR1NR3C1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097384-B1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| CN-101646654-B | Indazolyl sulfonamide derivatives useful as glucocorticoid modulators | ASTRAZENECA AB | 2012-03-28 | — | — | CN | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| US-8030340-B2 | Moderators of glucocorticoids receptor; antiinflamamtory agents; chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| CN-101646654-A | Indazolyl sulfonamide derivatives useful as glucocorticoid modulators | ASTRAZENECA AB SE | 2010-02-10 | — | — | CN | disclosed |
| EP-2097384-A1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | AstraZeneca AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| CN-101291914-A | Novel bicyclic sulfonamides for use as glucocorticoid receptor modulators in the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | CN | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1940800-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008063116-A1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007046747-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | CYP1A2 221/4885CYP17A1 30/4885CCR1 261/4885 |
| US-20090124607-A1 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases | NR3C1, NR3C2, MC2R | CYP1A2 579/4885CYP17A1 151/4885CCR1 275/4885 |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | NR3C1, NR3C2, MC2R | CYP1A2 226/4885CYP17A1 31/4885CCR1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.